HDAC6 Inhibition for Dual Restoration of Microtubule Stability and Autophagic Tau Clearance

Target: HDAC6 Composite Score: 0.484 Price: $0.54▲14.0% Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔴 Alzheimer's Disease 🧠 Neurodegeneration

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

Composite: 0.484

Top 70% of 1875 hypotheses

T5 Contested

Contradicted by evidence, under dispute

C+ Mech. Plausibility 15% 0.58 Top 64%

C+ Evidence Strength 15% 0.52 Top 54%

C Novelty 12% 0.42 Top 93%

C Feasibility 12% 0.48 Top 75%

B Impact 12% 0.65 Top 61%

B Druggability 10% 0.62 Top 41%

C Safety Profile 8% 0.45 Top 76%

C+ Competition 6% 0.55 Top 65%

B Data Availability 5% 0.60 Top 54%

C Reproducibility 5% 0.48 Top 75%

Evidence

7 supporting | 6 opposing

Citation quality: 50%

Debates

1 session B

Avg quality: 0.65

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Which tau PTMs are both disease-specific and druggable with selective small molecule inhibitors?

The debate highlighted promising PTMs like K280 acetylation and O-GlcNAcylation but didn't resolve which modifications can be selectively targeted without affecting physiological tau function. This specificity gap is critical for developing PTM-based therapeutics that avoid broad cellular toxicity. Source: Debate session sess_SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd_20260412-091129 (Analysis: SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd)

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

HDAC6 Inhibition for Dual Restoration of Microtubule Stability and Autophagic Tau Clearance starts from the claim that modulating HDAC6 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview HDAC6 Inhibition for Dual Restoration of Microtubule Stability and Autophagic Tau Clearance starts from the claim that Selective HDAC6 inhibitors (T-518, Tubastatin A, ACY-1215) simultaneously increase α-tubulin acetylation to restore microtubule stability disrupted by tau pathology, reduce tau hyperphosphorylation through improved vesicular transport, and enhance autophagic clearance of aggregated tau. The selectivity of HDAC6 over other HDACs avoids broad transcriptional dysregulation. Framed more explicitly, the hypothesis centers HDAC6 within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating HDAC6 or the surrounding pathway space around Microtubule dynamics and stabilization can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.52, novelty 0.42, feasibility 0.48, impact 0.65, mechanistic plausibility 0.58, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `HDAC6` and the pathway label is `Microtubule dynamics and stabilization`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of HDAC6 or Microtubule dynamics and stabilization is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. T-518, an orally active selective HDAC6 inhibitor, shows therapeutic potential in AD and tauopathy mouse models with favorable pharmacodynamics and superior HDAC6 selectivity over other HDACs. Identifier 34326423. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Tubastatin A/ACY-1215 improves cognition in AD transgenic mice by promoting tubulin acetylation, reducing Aβ production, and facilitating autophagic clearance of hyperphosphorylated tau without obvious adverse effects. Identifier 24844691. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. HDAC6 is a major regulator of MT acetylation status, and pharmacological HDAC6 inhibition improves axonal function and slows tauopathy progression. Identifier 34326423. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. HDAC6 modulates tau inclusion body formation and impairs autophagic clearance in ways that promote pathological tau removal. Identifier 25434725. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Tau itself is an inhibitor of deacetylase HDAC6 function, creating a pathological feedback loop where tau accumulation further disrupts microtubule acetylation homeostasis. Identifier 19457097. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. HDAC6 shows enriched association with neurodegenerative disease (score 0.39) in Open Targets Platform. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. HDAC6 knockout mice exhibit cognitive impairment rather than enhancement, contradicting the therapeutic hypothesis. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Tubastatin A demonstrates poor brain penetration in pharmacokinetic studies. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. ACY-1215 (Ricolinostat) clinical development has stalled in cancer indications due to combination toxicity concerns. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. No HDAC6 inhibitor has completed Phase 2 testing in AD, indicating persistent translational barriers. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. If pathological tau inhibits HDAC6, then HDAC6 inhibition would amplify the inhibitory effect, potentially exacerbating the pathological loop. Identifier 19457097. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.5276`, debate count `1`, citations `13`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates HDAC6 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "HDAC6 Inhibition for Dual Restoration of Microtubule Stability and Autophagic Tau Clearance". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting HDAC6 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers HDAC6 within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating HDAC6 or the surrounding pathway space around Microtubule dynamics and stabilization can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.52, novelty 0.42, feasibility 0.48, impact 0.65, mechanistic plausibility 0.58, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `HDAC6` and the pathway label is `Microtubule dynamics and stabilization`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of HDAC6 or Microtubule dynamics and stabilization is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

T-518, an orally active selective HDAC6 inhibitor, shows therapeutic potential in AD and tauopathy mouse models with favorable pharmacodynamics and superior HDAC6 selectivity over other HDACs. Identifier 34326423. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Tubastatin A/ACY-1215 improves cognition in AD transgenic mice by promoting tubulin acetylation, reducing Aβ production, and facilitating autophagic clearance of hyperphosphorylated tau without obvious adverse effects. Identifier 24844691. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

HDAC6 is a major regulator of MT acetylation status, and pharmacological HDAC6 inhibition improves axonal function and slows tauopathy progression. Identifier 34326423. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

HDAC6 modulates tau inclusion body formation and impairs autophagic clearance in ways that promote pathological tau removal. Identifier 25434725. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Tau itself is an inhibitor of deacetylase HDAC6 function, creating a pathological feedback loop where tau accumulation further disrupts microtubule acetylation homeostasis. Identifier 19457097. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

HDAC6 shows enriched association with neurodegenerative disease (score 0.39) in Open Targets Platform. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

HDAC6 knockout mice exhibit cognitive impairment rather than enhancement, contradicting the therapeutic hypothesis. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Tubastatin A demonstrates poor brain penetration in pharmacokinetic studies. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

ACY-1215 (Ricolinostat) clinical development has stalled in cancer indications due to combination toxicity concerns. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

No HDAC6 inhibitor has completed Phase 2 testing in AD, indicating persistent translational barriers. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

If pathological tau inhibits HDAC6, then HDAC6 inhibition would amplify the inhibitory effect, potentially exacerbating the pathological loop. Identifier 19457097. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.5276`, debate count `1`, citations `13`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates HDAC6 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "HDAC6 Inhibition for Dual Restoration of Microtubule Stability and Autophagic Tau Clearance".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting HDAC6 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Protein Aggregate Accumulation"] --> B["Autophagy Impairment"]
    B --> C["Toxic Species Build-up"]
    C --> D["Neuronal Dysfunction"]
    E["HDAC6 Autophagy Enhancement"] --> F["Phagophore Nucleation ↑"]
    F --> G["Cargo Recognition & Engulfment"]
    G --> H["Lysosomal Degradation"]
    H --> I["Aggregate Clearance"]
    I --> J["Neuroprotection"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style E fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style J fill:#1b5e20,stroke:#81c784,color:#81c784

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for HDAC6 from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

13 citations 7 with PMID Validation: 50% 7 supporting / 6 opposing

✓ For (7)

No supporting evidence

No opposing evidence

(6) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 7CLIN 4GENE 2EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
T-518, an orally active selective HDAC6 inhibitor,…	Supporting	CLIN	-	-	-	-	PMID:34326423	-
Tubastatin A/ACY-1215 improves cognition in AD tra…	Supporting	GENE	-	-	-	-	PMID:24844691	-
HDAC6 is a major regulator of MT acetylation statu…	Supporting	CLIN	-	-	-	-	PMID:34326423	-
HDAC6 modulates tau inclusion body formation and i…	Supporting	MECH	-	-	-	-	PMID:25434725	-
Tau itself is an inhibitor of deacetylase HDAC6 fu…	Supporting	MECH	-	-	-	-	PMID:19457097	-
HDAC6 shows enriched association with neurodegener…	Supporting	MECH	-	-	-	-	-	-
Multiple HDAC6-selective inhibitor chemotypes exis…	Supporting	MECH	-	-	-	-	-	-
HDAC6 knockout mice exhibit cognitive impairment r…	Opposing	GENE	-	-	-	-	-	-
Tubastatin A demonstrates poor brain penetration i…	Opposing	MECH	-	-	-	-	-	-
ACY-1215 (Ricolinostat) clinical development has s…	Opposing	CLIN	-	-	-	-	-	-
No HDAC6 inhibitor has completed Phase 2 testing i…	Opposing	CLIN	-	-	-	-	-	-
If pathological tau inhibits HDAC6, then HDAC6 inh…	Opposing	MECH	-	-	-	-	PMID:19457097	-
HDAC6 facilitates autophagosome-lysosome fusion; H…	Opposing	MECH	-	-	-	-	PMID:25434725	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 7

T-518, an orally active selective HDAC6 inhibitor, shows therapeutic potential in AD and tauopathy mouse model…▼

T-518, an orally active selective HDAC6 inhibitor, shows therapeutic potential in AD and tauopathy mouse models with favorable pharmacodynamics and superior HDAC6 selectivity over other HDACs

PMID:34326423

Tubastatin A/ACY-1215 improves cognition in AD transgenic mice by promoting tubulin acetylation, reducing Aβ p…▼

PMID:24844691

HDAC6 is a major regulator of MT acetylation status, and pharmacological HDAC6 inhibition improves axonal func…▼

HDAC6 is a major regulator of MT acetylation status, and pharmacological HDAC6 inhibition improves axonal function and slows tauopathy progression

PMID:34326423

HDAC6 modulates tau inclusion body formation and impairs autophagic clearance in ways that promote pathologica…▼

HDAC6 modulates tau inclusion body formation and impairs autophagic clearance in ways that promote pathological tau removal

PMID:25434725

Tau itself is an inhibitor of deacetylase HDAC6 function, creating a pathological feedback loop where tau accu…▼

Tau itself is an inhibitor of deacetylase HDAC6 function, creating a pathological feedback loop where tau accumulation further disrupts microtubule acetylation homeostasis

PMID:19457097

HDAC6 shows enriched association with neurodegenerative disease (score 0.39) in Open Targets Platform

Multiple HDAC6-selective inhibitor chemotypes exist with established structure-activity relationships

✗ Opposing Evidence 6

HDAC6 knockout mice exhibit cognitive impairment rather than enhancement, contradicting the therapeutic hypoth…▼

HDAC6 knockout mice exhibit cognitive impairment rather than enhancement, contradicting the therapeutic hypothesis

Tubastatin A demonstrates poor brain penetration in pharmacokinetic studies

ACY-1215 (Ricolinostat) clinical development has stalled in cancer indications due to combination toxicity con…▼

ACY-1215 (Ricolinostat) clinical development has stalled in cancer indications due to combination toxicity concerns

No HDAC6 inhibitor has completed Phase 2 testing in AD, indicating persistent translational barriers

If pathological tau inhibits HDAC6, then HDAC6 inhibition would amplify the inhibitory effect, potentially exa…▼

If pathological tau inhibits HDAC6, then HDAC6 inhibition would amplify the inhibitory effect, potentially exacerbating the pathological loop

PMID:19457097

HDAC6 facilitates autophagosome-lysosome fusion; HDAC6 inhibition may impair autophagic flux, trapping tau agg…▼

HDAC6 facilitates autophagosome-lysosome fusion; HDAC6 inhibition may impair autophagic flux, trapping tau aggregates rather than promoting clearance

PMID:25434725

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-13 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses: Disease-Specific Tau PTM Targets

Hypothesis 1: P300/CBP Acetyltransferase Inhibition to Block K280 Acetylation While Preserving Physiological Acetylation

Target: EP300 (p300)

Description: p300-mediated acetylation at K280 is disease-specific and blocks tau microtubule binding. Unlike pan-HDAC inhibitors, selective p300 inhibition with C646 or A-485 would block this pathogenic acetylation while preserving physiological acetylation at other sites (K163, K174) and avoiding broad deacetylase disruption that causes cytotoxicity.

**Supporting Evidence

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Disease-Specific Tau PTM Therapeutic Hypotheses

Hypothesis 1: P300/CBP Acetyltransferase Inhibition

Specific Weaknesses in the Evidence

Enzymatic Specificity Gap: The claim that p300 selectively mediates K280 acetylation lacks direct biochemical characterization. p300/CBP have overlapping substrate specificity and have been shown to acetylate multiple sites on tau beyond K280 (PMID: 25651121). Demonstrating selective p300-mediated K280 acetylation in human brain tissue has not been conclusively established.

Inhibitor Selectivity Concerns: While A-4

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Domain Expert Evaluation: Disease-Specific Tau PTM Drug Targets

Executive Summary

Of the seven hypotheses, none currently meet all criteria for an optimal therapeutic target: disease-specific causality, target druggability with selective chemical matter, acceptable safety window, and demonstrated CNS penetration. However, two hypotheses (P300 inhibition, PRMT5 inhibition) have sufficient chemical matter and target validation to justify near-term investment with appropriate risk mitigation. Four hypotheses require significant chemical matter development or causality validation. One

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▲ 1.6%

Volatility

Low

0.0145

Events (7d)

⚡ Price Movement Log Recent 12 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.504	▲ 9.3%	market_dynamics	2026-04-14 00:20
📄	New Evidence	$0.461	▼ 8.6%	market_dynamics	2026-04-13 20:53
📊	Score Update	$0.505	▲ 0.2%	market_dynamics	2026-04-13 20:41
📊	Score Update	$0.504	▲ 13.5%	market_dynamics	2026-04-13 20:40
📊	Score Update	$0.444	▼ 26.5%	market_dynamics	2026-04-13 17:42
💬	Debate Round	$0.604	▲ 87.2%	market_dynamics	2026-04-13 17:34
💬	Debate Round	$0.323	▼ 32.9%	market_dynamics	2026-04-13 17:13
💬	Debate Round	$0.481	▲ 1.1%	market_dynamics	2026-04-13 15:03
📄	New Evidence	$0.476	▲ 2.6%	market_dynamics	2026-04-13 14:55
📄	New Evidence	$0.464	▼ 11.0%	evidence_update	2026-04-13 14:19
📄	New Evidence	$0.521	▲ 13.3%	evidence_update	2026-04-13 14:19
✨	Listed	$0.460		post_process	2026-04-13 14:19

Clinical Trials (1) Relevance: 62%

0
Active

0
Completed

0
Total Enrolled

Untitled Trial Unknown

Unknown ·

📚 Cited Papers (4)

Tau--an inhibitor of deacetylase HDAC6 function.

Journal of neurochemistry (2009) · PMID:19457097

No extracted figures yet

Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.

Journal of Alzheimer's disease : JAD (2015) · PMID:24844691

No extracted figures yet

Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance.

Journal of molecular neuroscience : MN (2015) · PMID:25434725

No extracted figures yet

A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.

Scientific reports (2021) · PMID:34326423

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Which tau PTMs are both disease-specific and druggable with selective small molecule inhibitors? — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-13-gap-debate-20260412-094612-a2e3bd09. The debate highlighted promising PTMs like K280 acetylation and O-GlcNAcylation but didn't resolve which mod …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Low Efficiency Resource Efficiency Score

0.00

7.2th percentile (776 hypotheses)

Tokens Used

16,685

KG Edges Generated

1,140

Citations Produced

Cost Ratios

Cost per KG Edge

2085.62 tokens

Lower is better (baseline: 2000)

Cost per Citation

1283.46 tokens

Lower is better (baseline: 1000)

Cost per Score Point

36350.76 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.000

10% weight of efficiency score

Adjusted Composite

0.484

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.470	0.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for HDAC6.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for HDAC6 →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (8)

HDAC6 MGEA5 (OGA)OGA h-46e028b6 h-f86127b5 microtubule_dynamics_and_stabilization neurodegeneration o_glcnacase___glycosylation_signaling

Related Hypotheses

HDAC6 Selective Inhibition to Restore Acetylation Balance and Microtubule Stability

Score: 0.643 | structural biology

HDAC6 Inhibitor Therapy for Pan-Neurodegenerative Protein Homeostasis

Score: 0.450 | neurodegeneration

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration

Score: 0.907 | neurodegeneration

Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse

Score: 0.895 | neurodegeneration

SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence

Score: 0.893 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

6.6 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF human iPSC-derived cortical neurons harboring MAPT P301L mutations are treated with 1 μM Tubastatin A (HDAC6 inhibitor) for 72 hours, THEN α-tubulin acetylation will increase by ≥3-fold relative to vehicle-treated controls AND insoluble Sarkozy-positive tau aggregates will decrease by ≥30% as measured by filter retardation assay.

pending conf: 0.55

Expected outcome: α-tubulin acetylation increased ≥3-fold AND insoluble tau aggregates decreased ≥30% (direction: improvement)

Falsified by: No significant change in α-tubulin acetylation (<1.5-fold) OR no reduction in tau aggregate load (<15% decrease) would disconfirm the mechanistic prediction.

Method: iPSC-derived cortical neurons from MAPT P301L carriers (n≥3 lines), HDAC6 inhibitor treatment, acetylated α-tubulin Western blot quantification, Sarkozy filter retardation assay

IF 3xTg-AD mice (expressing mutant APP, PS1, and tau) receive chronic HDAC6 inhibitor ACY-1215 at 25 mg/kg via intraperitoneal injection 5 days/week for 12 weeks starting at 6 months of age, THEN microtubule density in hippocampal CA1 neurons will normalize to levels comparable to wild-type mice AND phosphorylated tau (AT8) will decrease by ≥40% in hippocampus relative to vehicle-treated 3xTg-AD mice.

pending conf: 0.48

Expected outcome: Microtubule density restored to wild-type levels AND hippocampal AT8 tau signal decreased ≥40% (direction: improvement)

Falsified by: Microtubule density remains >2 standard deviations below wild-type OR AT8 tau signal decreases <20% would disconfirm the in vivo mechanistic claim.

Method: 3xTg-AD mice (n≥10/group, both sexes), ACY-1215 or vehicle treatment for 12 weeks, electron microscopy for microtubule density quantification in CA1 pyramidal neurons, AT8 immunohistochemistry with stereological counting

Knowledge Subgraph (6 edges)

Mechanism Pathway for HDAC6

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    h_f86127b5["h-f86127b5"] -->|targets| HDAC6["HDAC6"]
    h_46e028b6["h-46e028b6"] -->|targets| MGEA5__OGA_["MGEA5 (OGA)"]
    MGEA5__OGA__1["MGEA5 (OGA)"] -->|associated with| neurodegeneration["neurodegeneration"]
    HDAC6_2["HDAC6"] -->|involved in| microtubule_dynamics_and_["microtubule_dynamics_and_stabilization"]
    MGEA5__OGA__3["MGEA5 (OGA)"] -->|involved in| o_glcnacase___glycosylati["o_glcnacase___glycosylation_signaling"]
    MGEA5__OGA__4["MGEA5 (OGA)"] -->|co associated with| OGA["OGA"]
    style h_f86127b5 fill:#4fc3f7,stroke:#333,color:#000
    style HDAC6 fill:#ce93d8,stroke:#333,color:#000
    style h_46e028b6 fill:#4fc3f7,stroke:#333,color:#000
    style MGEA5__OGA_ fill:#ce93d8,stroke:#333,color:#000
    style MGEA5__OGA__1 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style HDAC6_2 fill:#ce93d8,stroke:#333,color:#000
    style microtubule_dynamics_and_ fill:#81c784,stroke:#333,color:#000
    style MGEA5__OGA__3 fill:#ce93d8,stroke:#333,color:#000
    style o_glcnacase___glycosylati fill:#81c784,stroke:#333,color:#000
    style MGEA5__OGA__4 fill:#ce93d8,stroke:#333,color:#000
    style OGA fill:#ce93d8,stroke:#333,color:#000

Predicted Protein Structure

🔮 HDAC6 — AlphaFold Prediction A0A2R8Y559 Click to expand 3D viewer

AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Which tau PTMs are both disease-specific and druggable with selective small molecule inhibitors?

neurodegeneration | 2026-04-13 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Edit History

Action	Actor	Timestamp	Reason	Changes
update	codex:51	2026-04-26T14:44	Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d	Changes recorded
update	codex:51	2026-04-26T14:44	Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d	Changes recorded

View full edit history (JSON)

Same Analysis (1)

Selective OGA Inhibition as 'Tau Stabilization' Strategy Without Phosp

Score: 0.46 · MGEA5 (OGA)

→ View all analysis hypotheses

HDAC6 Inhibition for Dual Restoration of Microtubule Stability and Autophagic Tau Clearance

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 7

✗ Opposing Evidence 6

Novel Therapeutic Hypotheses: Disease-Specific Tau PTM Targets

Hypothesis 1: P300/CBP Acetyltransferase Inhibition to Block K280 Acetylation While Preserving Physiological Acetylation

Critical Evaluation of Disease-Specific Tau PTM Therapeutic Hypotheses

Hypothesis 1: P300/CBP Acetyltransferase Inhibition

Specific Weaknesses in the Evidence

Domain Expert Evaluation: Disease-Specific Tau PTM Drug Targets

Executive Summary

Price History

Clinical Trials (1) Relevance: 62%

📚 Cited Papers (4)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (1)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (8)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (6 edges)

associated with (1)

co associated with (1)

involved in (2)

targets (2)

Mechanism Pathway for HDAC6

Predicted Protein Structure

Source Analysis

Which tau PTMs are both disease-specific and druggable with selective small molecule inhibitors?

Community Feedback

Edit History

Same Analysis (1)